Fennec Pharma (FENC)
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a f...
- Open
- 11.470
- High
- 11.650
- Low
- 11.220
- Prev. Close
- 11.350
- Volume
- 210.74K
- Turnover
- 2.40M
- Avg Price
- 11.377
- Bid/Ask Ratio
- --
- Amplitude
- 3.79%
- 52wk High
- 13.250
- Volume Ratio
- 1.61
- Turnover Ratio
- 1.29%
Fennec Pharma Analyst Rating
View moreForecast & Rating
Aug 12, 2026Price forecast
$17.6756.48%
Forecast & RatingStrong buy
6analysts
- Strong buy66.67%
- Buy33.33%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 17 at 03:33 PM
Fennec Pharmaceuticals publishes corporate presentation highlighting PEDMARK expansion for cisplatin-induced hearing loss prevention
- Baystreet · Aug 11 at 10:41 AM
Air Canada, Amerigo, Aya at 52-Week Highs on News
- Quartr · Aug 11 at 09:44 AM
FENC: Q2 revenue up 78% year-over-year, with record enrollments and strong growth momentum
- rttnews · Aug 10 at 04:53 AM
Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE
- PUBT · Aug 5 at 06:11 AM
Fennec Pharmaceuticals schedules second-quarter 2026 results call
- PUBT · Aug 4 at 03:06 PM
Fennec Pharmaceuticals former director Rosty Raykov disposes of 10,000 common shares worth $95,800
